Literature DB >> 9679955

Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells.

M A Morse1, H K Lyerly, E Gilboa, E Thomas, S K Nair.   

Abstract

Dendritic cells (DCs), matured by CD40-ligand (CD40L), undergo marked changes in their ability to process and present antigen, resulting in augmented lymphocyte stimulatory activity. We demonstrate that the form of the tumor antigen (peptide or genetic material) used to load the DCs dictates the required sequence of antigen loading and maturation for antitumor immunotherapy. Optimal stimulation of carcinoembryonic antigen (CEA)-specific CTLs by peptide-loaded DCs occurs when DCs from cancer patients are matured with CD40L before exposure to CEA peptide, whereas optimal stimulation by RNA-transfected DCs occurs when the DCs are loaded with CEA RNA before maturation with CD40L.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679955

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Active immunization of humans with dendritic cells.

Authors:  M V Dhodapkar; N Bhardwaj
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy.

Authors:  Laila Samady; Emanuela Costigliola; Luci MacCormac; Yvonne McGrath; Steve Cleverley; Caroline E Lilley; Jill Smith; David S Latchman; Benny Chain; Robert S Coffin
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 3.  Modulation of antitumor responses by dendritic cells.

Authors:  Johannes Vieweg; Andrew Jackson
Journal:  Springer Semin Immunopathol       Date:  2005-01

4.  Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.

Authors:  Louise J Young; Nicholas S Wilson; Petra Schnorrer; Adele Mount; Rachel J Lundie; Nicole L La Gruta; Brendan S Crabb; Gabrielle T Belz; William R Heath; Jose A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-31       Impact factor: 11.205

Review 5.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

Review 6.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

7.  Phenotypic and functional characteristics of dendritic cells derived from human peripheral blood monocytes.

Authors:  Ling-ling Tang; Zhe Zhang; Jie-sheng Zheng; Ji-fang Sheng; Ke-zhou Liu
Journal:  J Zhejiang Univ Sci B       Date:  2005-12       Impact factor: 3.066

Review 8.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  IL-10 down-regulates costimulatory molecules on Mycobacterium tuberculosis-pulsed macrophages and impairs the lytic activity of CD4 and CD8 CTL in tuberculosis patients.

Authors:  S de la Barrera; M Aleman; R Musella; P Schierloh; V Pasquinelli; V Garcia; E Abbate; M del C Sasiain
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

10.  Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli.

Authors:  M-Y Bae; N-H Cho; S-Y Seong
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.